Residual Disease in Spondyloarthritis: What's Being Missed by DMARDs?
(MedPage Today) -- In spondyloarthritis (SpA), the wealth of biologic and disease-modifying anti-rheumatic drug (DMARD) options still leaves some patients unsatisfied with their treatment outcomes, most likely due to residual disease. This year...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.